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Replication-deficient adenoviral (rAd5) vaccines containing codon-optimized E1, E2, E4, and E7 genes of canine oral papillomavirus
(COPV) were tested singly or in combination to determine which vaccines could protect against mucosal challenge with COPV. In three
studies, groups of 4–6 beagle dogs were immunized subcutaneously (s.c.) with 1011 rAd5 at 8–10 weeks and 4–6 weeks prior to challenge
with infectious COPV particles at multiple oral mucosal sites. Control dogs were immunized with equivalent doses of rAd5 expressing
human papillomavirus (HPV) type 16 L1 (rAd5-HPV-16 L1). In the first study, complete protection from COPV-induced papillomas was
achieved by immunization with rAd5 vaccine combinations expressing either E1 + E2 or E1 + E2 + E4 + E7; whereas two of six dogs
immunized with rAd5-E4 + rAd5-E7 and six of six rAd5-HPV16-L1-immunized control dogs developed oral papillomas. In two subsequent
studies, rAd5-E1 and rAd5-E2 vaccines were tested singly or in combination to assess levels of protective immunity to COPV challenge.
Subcutaneous immunization with either one or two doses of rAd5 expressing the COPV E1 and E2 genes could protect >90% of challenged
dogs from wart formation. In contrast, all eight dogs immunized with rAd5-HPV-16 L1 developed papillomas at multiple sites. Protection
was accompanied by significant IFN-g responses to COPV E1 and E2 peptides. Partial protection was conferred by two immunizations with
either rAd5-E1 (6 of 9 protected) or rAd5-E2 (8 of 9 protected). These data indicate that rAd5 expressing papillomavirus E1 and E2 proteins
can induce strong protective responses even in outbred populations under practical immunization conditions.
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Papillomaviruses infect epithelia of skin and mucous
membranes and cause benign or malignant tumors in
animals and man. Of more than 100 different types of0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.03.022
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1 These authors contributed equally to the study.human papillomaviruses (HPV), over 30 infect the mucosal
epithelium of the genital tract, resulting in a variety of
diseases including condyloma acuminata (genital warts),
cervical dysplasia, and cervical carcinoma (Bosch et al.,
2002; zur Hausen and de Villiers, 1994). High-risk types of
HPV, in particular HPV-16, -18, -31, -33, -45 and others, are
major risk factors for the development of cervical cancer, of
which 500,000 cases are diagnosed annually (Landis et al.,
1999). Overall, 99.7% of all cervical cancers contain HPV
DNA (Bosch et al., 2002). In 1995, the International05) 208 – 218
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strong association between infection with particular genital
types of HPV and cervical cancer by designating HPV-16
and -18 as ‘‘carcinogenic to humans’’ and types 31 and 33 as
‘‘possibly carcinogenic to humans’’ (Anonymous, 1995).
Low-risk HPV types -6, -11, -42, -43, and -44 are associated
with low-grade cervical intraepithelial neoplasia and genital
warts. The latter, caused predominantly by HPV-6 and -11
(Brown et al., 1993; Gissmann et al., 1983), is among the
most common sexually transmitted disease worldwide,
occurring at an incidence rate of 2.4 per 1000 per year in
the developed world (Birley, 2001). The high level of
mortality and morbidity associated with high- and low-risk
HPV infections and the attendant economic and social costs
of HPV-associated disease underscore a critical need to
develop effective intervention strategies. Due to recent
advances in prophylactic vaccines for HPV (Jansen and
Shaw, 2004; Koutsky et al., 2002; Stanley, 2003), vaccine-
based approaches appear to offer significant promise for the
prevention and control of HPV-associated disease.
In addition to requiring differentiating epithelium for
completion of their life cycle, papillomaviruses are
extremely species-specific in that they rarely infect hosts
other than their natural one (Campo, 2002). Xenotransplan-
tation and grafting models have been established to study
the pathogenesis of high- and low-risk HPVs and to
demonstrate in vivo neutralization of VLP-based vaccines
(Brown et al., 2001; Bryan et al., 1997; Tewari et al., 2000).
Furthermore, several models – bovine papillomavirus
(BPV), cottontail rabbit papillomavirus (CRPV), and canine
oral papillomavirus (COPV)–are of value for the compara-
tive study of papillomavirus disease and intervention
(Stanley et al., 1997). Of these, COPV is a useful model
for mucosatropic papillomaviruses, causing warts at oro-
pharyngeal sites that are morphologically similar to genital
warts associated with HPV-6 and -11 infections (Nicholls et
al., 1999, 2001a, 2001b). Following natural or experimental
COPV infection through abraded mucosal epithelium, warts
develop 4–6 weeks post-challenge and then spontaneously
regress over the next 4–8 weeks. The time course of wart
development and regression is highly reproducible within
and between laboratories; therefore, COPV represents a
reliable model for proof-of-principal studies involving
papillomavirus vaccines.
The COPV model has been used to demonstrate the
protective efficacy of VLP- or DNA-containing vaccines
designed to elicit neutralizing antibodies to the L1 capsid
protein (Stanley et al., 2001; Suzich et al., 1995; Yuan et al.,
2001). Antibodies to conformational sites on L1 correlate
with protection against infection. However, while antibodies
to conformational antigens on the viral capsid protect, they
do not appear to mediate the rejection of established
papillomavirus lesions (Nicholls et al., 1999). In contrast,
interventive vaccine strategies targeting early (E) gene
products expressed during early and late stages of papil-
lomavirus-induced carcinogenesis can enhance tumorregression and protect from recurrent disease (Brandsma et
al., 2004; Moore et al., 2002a, 2002b, 2003).
Since disease incidence and progression are readily
monitored in the COPV model, we have chosen this model
to ask whether disease outcome could be influenced by
vaccination with COPV E proteins expressed with repli-
cation-deficient recombinant adenovirus (rAd) constructs in
the absence of neutralizing antibodies to L1 or L2 capsid
proteins. While VLP vaccination has provided outstanding
levels of protection in both animal models and human
clinical trials, a VLP-based vaccine would not be expected
to elicit the type of cell-mediated immune responses
required for therapeutic treatment of late-stage (CIN-II,
III) cervical carcinomas that largely express a limited
spectrum of early gene products (Baker et al., 1987;
Schwartz et al., 1985). To progress to the therapeutic use
of Ad5-based vaccines expressing early gene products, it is
instructive first to determine if levels of early gene
expression and routes of antigen presentation are suffi-
ciently robust to evoke a protective immune response to
virus challenge in a prophylactic model. We report here that
recombinant, replication-defective adenoviral (rAd) vac-
cines expressing the COPV early genes can prevent or
greatly reduce disease burden in beagle dogs challenged at
mucosal sites with COPV.Results
In vitro expression
We evaluated the expression of COPV E1, E2, E4, and
E7 and HPV16 L1 in two cell lines, 293 and T rex, infected
with rAd containing codon-optimized COPV E or HPV L1
genes under the control of the tetracycline operator (Figs.
1A–E). Predicted molecular weights based on primary
amino acid sequences (Los Alamos HPV sequence data-
base, http://www.hpv-web.lanl.gov/stdgen/virus/hpv) and
Vector NTI, ver. 6 software, are COPV E1: 67,979 d;
COPV E2: 43,092 d; COPV E4: 12,992 d; COPV E7:
10,798 d; HPV 16 L1: 59,549 d. COPV and HPV proteins
of expected molecular weights were expressed in 293 cells
where no tetracycline repressor is produced. In contrast,
there was little protein expression in the T rex cell line
where the tetracycline repressor is expressed. These rAd
vaccines were used to immunize dogs prior to challenge
with COPV.
Protection against COPV infection with rAd-COPV-E1 and
-E2 vaccines
Three studies were performed to evaluate the protective
properties of rAd vaccines expressing COPV early genes
(Table 1).
In Study #1, groups of 6 beagle dogs (age 12–15 weeks)
were immunized subcutaneously with two doses of rAd
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challenge. Control animals received the same doses of HPV-
16 L1 rAd. Dogs were challenged with COPV at 10 oral
mucosal sites on week 0 and monitored weekly for wart
development, number, and size. All dogs vaccinated with
either a combination of rAd-COPV-E1 + -E2 (Table 1,
Study #1, Group 1) or a combination of rAd-COPV-E1 +
-E2 + -E4 + -E7 (Group 3) were completely protected from
wart development. In contrast, 2 of 6 dogs immunized with
rAd-COPV-E4 + -E7 developed warts by week 6 that
persisted to week 13. Although it may be that better levels
of protection are achieved with rAd-COPV-E1 and -E2constructs than with combined inocula containing rAd-
COPV-E4 and -E7, it is also possible that differences in
levels of protection between Groups 1 (rAd-COPV-E1, -E2)
and 2 (rAd-COPV-E4, -E7) in Study #1 could be due to
lower levels of E4 or E7 expression, as suggested by
Western blot data (Fig. 1). Also, all 6 rAd-HPV-16 L1-
immunized dogs developed oral mucosal warts by week 8
which persisted past week 10.
Studies #2 and #3 were performed to compare the level
of protection induced by 1–2 doses of either rAd-COPV-E1
or rAD-COPV-E2 vaccines alone or in combination
administered 10 to 6 weeks prior to challenge with COPV
at 10 oral mucosal sites (Table 1). Within Study #2, dogs in
Group #1 received only a single inoculation of rAd-COPV-
E1 + -E2 10 weeks prior to challenge.
For dogs in Study #2, Group 2, that were immunized
twice with the combination rAd COPV-E1 + -E2 vaccine,
2 of 5 transiently developed small (1- to 2-mm diameter)
warts at several sites between weeks 8 and 10. However,
warts were greatly reduced in number and size when
compared to warts observed at multiple challenge sites in
dogs immunized with rAd-HPV-16 (Table 1, Study #2,
Group 5; Fig. 2). Comparable results were obtained for
dogs in Group 1 receiving a single dose of the combined
E1 + E2 vaccine at week 10 with the exception that
none of the 5 dogs developed warts during the course of
the study. Partial protection was conferred by two doses
of rAd-COPV-E1 or -E2 vaccines administered without
combination (Table 1, Study #2, Groups 3 and 4). For
dogs in Group 3 receiving the E1 vaccine, 3 of 5 had
warts at challenge sites between weeks 6 and 10. As
before, wart numbers and mean diameters were greatly
reduced compared to those in the control Group 5
receiving rAd-HPV-16 L1. One of five dogs receiving
the E2 vaccine had transient, small warts at 2–3 sites at
week 8 (Group 4). In contrast, all 4 dogs in Group 5
vaccinated with two doses of rAd HPV-16-L1 developed
warts from weeks 7 to 11 post-challenge.Fig. 1. Western blot expression analysis of codon-optimized COPV E1, E2,
E4, E7, and HPV16 L1 genes in rAd. Recombinant adenovirus (rAd)
constructs were generated to contain a CMV-TO (tetracycline operator)
promoter to drive expression of the COPV or HPV gene product. In T rex
cells, expression from the CMV-TO promoter is repressed due to the
presence of the tetracycline repressor. Expression from the CMV-TO
promoter is de-repressed in 293 cells, which do not express the Tetracycline
repressor. Immunoblots were analyzed using goat sera generated against
each of the COPV and HPV proteins. (A) Western blot analysis of rAd5
expressing COPV E1 (67,979 Da) in T rex or 293 cells infected with 0, 108,
or 109 recombinant adenovirus particles. (B) Western blot analysis of rAd5
expressing COPV E2 (43,092 Da) in T rex or 293 cells infected with 0, 108,
109 viral particles. (C) Western blot analysis of rAd5 expressing COPV E4
(12,992 Da) in T rex cells infected with 108 viral particles or in 293 cells
infected with 0, 108, or 109 viral particles. (D) Western blot analysis of
rAd5 expressing COPV E7 (10,798 Da) in 293 cells infected with 0, 108, or
109 viral particles. A lysate of 293 cells infected with rAd-COPV E4 was
included in this blot to confirm specificity of sera (lane 4). (E) Western blot
analysis of rAd5 expressing HPV16-L1 (59,549 Da) in T rex or 293 cells
infected with 0, 108, 109 viral particles.
Table 1
Protection of beagle dogs against COPV challenge after immunization with rAd expressing COPV E-proteins
rAd vaccine Number of dogs with warts/Total number of dogs
Week 0–4 Week 6 Week 8 Week 10 Week 13 Week 16
Study #1
Group 1 E1+E2 0/6 0/6 0/6 0/6 0/6 0/6
Group 2 E4+E7 0/6 2/6 1/6 2/6 2/6 0/6
Group 3 E1+E2+E4+E7 0/6 0/6 0/6 0/6 0/6 0/6
Group 4 HPV-16-L1 0/6 4/6 6/6 6/6 5/6 5/6
Study #2
Group 1 E1+E2 (1 dose) 0/5 0/5 0/5 0/5 0/5 0/5
Group 2 E1+E2 (2 doses) 0/5 0/5 1/5 1/5 0/5 0/5
Group 3 E1 0/5 1/5 2/5 1/5 0/5 0/5
Group 4 E2 0/5 0/5 1/5 0/5 0/5 0/5
Group 5 HPV-16-L1 0/4 2/4 4/4 4/4 1/4 0/4
Study #3
Group 1 E1 0/4 0/4 0/4 0/4 0/4 0/4
Group 2 E2 0/4 0/4 0/4 0/4 0/4 0/4
Group 3 HPV-16-L1 0/4 3/4 3/4 4/4 1/4 ND
Combined results of Studies #1–3
Group 1 E1+E2 (1 and 2 doses) 0/16 0/16 1/16 1/16 0/16 0/16
Group 2 E1 0/9 1/9 2/9 1/9 0/9 0/9
Group 3 E2 0/9 0/9 1/9 0/9 0/9 0/9
Group 4 HPV 16 L1 0/14 9/14 13/14 14/14 7/14 5/14
K.B. Johnston et al. / Virology 336 (2005) 208–218 211For Study #3, groups of 4 dogs each were immunized
with two doses of either E1 or E2 vaccines singly or a
negative control HPV-16-L1 vaccine (Table 1). In this
experiment, all dogs immunized with either E1 or E2
vaccines were completely protected against oral mucosal
challenge with COPV; whereas 4 of 4 dogs in control Group
3 developed warts by week 10.
Combining the results of vaccine Studies #1–3 (Table 1),
14 of 14 dogs in control groups receiving rAd-HPV-16-L1
developed oral mucosal warts between weeks 6 and 10 post-
challenge. For dogs receiving one or two doses of the
combined rAd-COPV-E1 + -E2 vaccines, 2 of 16 had a few
small warts which developed and then regressed rapidly
between 8 and 10 weeks post-challenge. Three of nine E1-
vaccinated dogs (Studies #2, 3) developed warts by week 6
that regressed between weeks 10 and 13; whereas 1 of 9
dogs vaccinated with the E2 vaccine had small warts that
regressed between weeks 8 and 9.
Statistical analysis of papilloma development
In Study #2, the mean diameters of papillomas in the
E2 and E1 + E2 groups at weeks 7–11 were significantly
smaller (P < 0.05) than the mean diameters of papillomas
in the control (HPV16-L1) groups. It should be noted that
the E1 + E2 group at week 9 gave a P value of 0.11, likely
due to the variability of wart development/regression in the
control group at that time point. Dogs in the E1 immu-
nized group had significantly smaller mean wart diameters
only in weeks 8, 10, and 11, suggesting that COPV E1only partially protected against viral challenge in this
study.
With respect to wart numbers, a similar trend was
observed in all three experimental groups. The E2 and E1 +
E2 groups had significantly fewer (P < 0.05) warts in weeks
7–11 when compared to the control group with the exception
of weeks 9 and 10 in the E1 + E2 group. The E1 immunized
group had significantly fewer warts only in week 11.
In Study #3, the mean diameters of papillomas in all of the
experimental groups (E1, E2, and E1 + E2) were significantly
smaller (P < 0.05) than those in the control group in weeks
6–8, week 10, and week11, with a trend toward significance
in week 9 (P = 0.06). Significant differences in numbers of
papillomas were noted in weeks 7 and 11 in this study, again
with a trend toward significance in weeks 6 and 8–10. One
control dog did not begin developing warts until week 10.
These warts progressed through week 15 and did not undergo
complete regression until week 16. The delay in onset of wart
development in this dog (ABX7) significantly increased the
variability of wart numbers within the control group,
resulting in reduced statistical significance of wart numbers
in experimental groups when compared to controls. However,
the results of this study were clear with complete protection in
the vaccinated groups and wart development found only in
the control group.
IFN-c ELISpot responses to E1 and E2 peptides
Peripheral blood mononuclear cells (PBMCs) were
collected from all dogs in Studies #2 and #3 at 10 weeks
Fig. 2. Mean wart numbers and diameters. Once a week, each dog was examined for wart development at challenge sites. The total number of warts per animal
and the diameter of each wart were measured using manual calipers. Wart development was captured by photographic documentation. Mean wart diameters
were determined by measuring the diameter of individual papillomas in mm and calculating the mean diameter per group. In a similar manner, the mean
number of warts was determined by counting the total number of warts per dog and calculating the mean number of warts per group. Mean wart diameters/
numbers reflect progression and regression of warts in immunized and non-immunized animals. (A) Mean wart diameters in Studies 2 and 3 from week 5
through 16 post-challenge. (B) Mean number of warts in Studies 2 and 3 from week 5 through 16 post-challenge.
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rAd vaccination #2) prior to COPV challenge as well as
just prior to challenge (week 0) and at weeks 4, 8, 12, and
16 post-challenge. PBMCs were stimulated with E1 or E2
peptides and then tested in the canine IFN-g ELISpot
assay. For Study #2, ELISpot responses were detected
against E1 and E2 peptides 4 weeks after the first
immunization (week 10) with rAd in most dogs
receiving either COPV-rAd-E1, -E2 or -E1 + E2 vaccines;
in contrast, little or no responses were detected at this time
point to E1 or E2 in PBMC from negative control dogs
receiving rAd- HPV16-L1 (Fig. 3). Following challenge
with COPV, ELISpot responses remained elevated over
those of controls in most dogs immunized with E1, E2, or
E1 + E2 vaccines for up to 12 weeks post-challenge. In
Study #3, E1 and E2 IFN-g ELISpot responses detected 4
weeks after the first immunization (week 10) were
elevated following the second immunization and remained
elevated throughout the remainder of the study over
control levels obtained with PBMC from rAd-HPV-16L1-
immunized dogs (Fig. 4).
There was no apparent correlation between IFN-g
ELISpot responses and protection from COPV-induced
wart development, in part because of the low number of
unprotected dogs in Studies #1–3 (Table 1). Among thethree rAd-E1-immunized dogs (99ACV2, 99AHQ3,
99ACM1) in Study #2 that developed small, transient
warts at challenge sites, all had low to moderate IFN-g
ELISpot responses to E1 peptides (Fig. 3A). One dog
(99ACM1) appeared to have an E1-specific anamnestic
response around week 12 following wart development and
regression between weeks 8 and 10 (Fig. 3A). Interest-
ingly, the only rAd-E2-immunized dog in Study #2,
Group 4 ,to develop warts (99AIS2; week 8) had no
detectable ELISpot response to E2 peptides (Fig. 3B).
However, among the dogs in Group 2 immunized with
rAd-E1 + -E2, dog 99AG04 had the highest IFN-g
ELISpot responses to both E1 and E2 peptides and yet
was one of two dogs in Group 2 (the other being
99AAE4) to develop warts (weeks 8–10). Thus, there
appears to be no straightforward relationship between
IFN-g ELISpot responses to E1 or E2 and development of
papillomavirus-induced lesions. Smyth et al. (2004) also
reported a similar lack of correlation between IFN-g
ELISpot responses and clearance of HPV-16-associated
anogenital intraepithelial neoplasia in patients immunized
with an HPV-16 L2/E6/E7 fusion protein and boosted
with HPV-16 L2/E6/E7-expressing vaccinia. Other
immune effector mechanisms not measured in our study
or that of Smyth et al. (2004)–e.g., CTL or NK
Fig. 3. IFN-g ELISpot responses for Study #2. IFN-g responses on y-axes are given as spot forming cells (SFC) per 106 cells. (A) PBMC from dogs in Group 3
immunized with COPV rAd-E1 and stimulated with E1 peptides; (B) PBMC from dogs in Group 4 immunized with COPV rAd-E2 and stimulated with E2
peptides; (C) PBMC from dogs in Group 5 immunized with rAd-HPV16 L1 and stimulated with E1 peptides; (D) PBMC from dogs in Group 1 immunized
with 2 doses of rAd-E1 + -E2 and stimulated with E1 peptides; (E) PBMC from dogs in Group 1 immunized with 2 doses of rAd-E1 + -E2 and stimulated with
E2 peptides; (F) PBMC from dogs in Group 5 immunized with rAd-HPV16 L1 and stimulated with E2 peptides.
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regression of papillomavirus-induced lesions.Discussion
This study provides strong support for the use of rAd
vaccines expressing codon-optimized E1 and E2 genes in
preventing papillomavirus-induced warts at mucosal sites.
Immunization with rAd-E1 and -E2 in combination
protected 14 of 16 dogs from development of papillomas
following experimental COPV infection in contrast to 0 of
10 dogs protected after immunization with rAd-HPV16-L1
(Table 1, Studies #1 and 2). Combined immunization with
rAd-E1, + E2, + E4, + E7 also conferred complete
protection (6 of 6, Study 1). However, since rAd-E4 + E7
combined vaccines were only partially protective, it
appears that rAd-E1 and E2 vaccines are required to
achieve a higher level of protection. When used alone, the
rAd-E1 vaccine protected 6 of 9 dogs (Studies #2 and 3).
Also, in rAd-E1-immunized dogs, mean wart diameters
(¨1–2 mm) were substantially less than those of control
dogs (¨4–8 mm), and warts persisted in each dog for
only 2–3 weeks as opposed to 6–8 weeks in the controlgroup. Following immunization with the rAd-E2 vaccine,
8 of 9 dogs were completely protected; the remaining dog
had 6 warts approximately 1–2 mm in diameter at 8
weeks post-challenge. Overall, vaccines comprised of
rAd-E1 + -E2 or rAd-E2 conferred a high degree of
protection (22 of 25 protected) in dogs challenged with
COPV at multiple sites.
Immunization with non-structural, early papillomavirus
proteins has been shown to be effective both as a preventive
and a therapeutic strategy. E1 and E2 are absolutely required
for the replication of viral genomes (Spalholz et al., 1993)
and, as such, they provide potentially advantageous targets
for immune clearance of papillomavirus-infected keratino-
cytes that support replication. Selvakumar et al. (1995)
reported that immunization with E1 or E2 proteins
significantly enhanced the rate of regression of cottontail
rabbit papillomavirus (CRPV)-induced papillomas. Also,
combined DNA vaccination with E6, E1, E2, and E7
plasmids administered by particle-mediated gene gun
inoculation conferred complete protection from CRPV-
mediated wart development in rabbits (Han et al., 1999).
A further study in rabbits involving particle-mediated DNA
delivery of plasmids encoding E1 and E2 resulted in a high
level of protection against CRPV challenge (Han et al.,
Fig. 4. IFN-g ELISpot responses for Study #3. IFN-g responses on y-axes are given as spot forming cells (SFC) per 106 cells. (A) PBMC from dogs in Group 1
immunized with COPV rAd-E1 and stimulated with E1 peptides; (B) PBMC from dogs in Group 2 immunized with COPV rAd-E2 and stimulated with E2
peptides; (C) PBMC from dogs in Group 3 immunized with rAd-HPV16 L1 and stimulated with E1 peptides; (D) PBMC from dogs in Group 3 immunized
with rAd-HPV16 L1 and stimulated with E2 peptides.
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vaccinations with an adenovirus vector expressing CRPV
E2 have resulted in a substantial reduction in the number
and size of papillomas at CRPV challenge sites (Brandsma
et al., 2004). Regarding prior studies with COPV, Moore et
al. (2002a, 2002b) have shown that intraepithelial DNA
immunization with a plasmid encoding a codon-optimized
COPV E1 gene sequence protected 6 of 6 dogs from COPV
challenge of oral mucosa; whereas 0 of 6 was protected after
immunization with DNA encoding a wild-type COPV E1
gene. DNA plasmids encoding codon-optimized COPV E1
or E2 genes administered therapeutically 2 and 4 weeks
post-challenge also conferred significant levels of protection
from outgrowth of papillomas (Moore et al., 2003). In the
study by Moore et al. (2003), the E2 vaccine appeared to be
more highly effective in that nearly complete protection was
achieved, while E1-vaccinated dogs developed smaller
warts in fewer than 50% of challenge sites when compared
to control dogs receiving DNA vaccine containing open
reading frames of hepatitis B surface antigen. Similarly, in
the present study, a greater percentage of dogs were
protected with the rAd-E2 vs. the rAd-E1 vaccine (8/9 vs.
6/9). Moreover, qualitatively, there appeared to be a trend
for greater levels of IFN-g ELISpot responses in E2- vs. E1-
immunized dogs (Figs. 3A vs. 3B; Figs. 4A vs. 4B). It is
unclear whether the increased IFN-g ELISpot responses in
E2-immunized dogs reflect an enhanced TH1-type cellularimmune response that favors wart clearance. However,
lymphocytic infiltrates frequently observed in regressing
warts are interpreted as a clear indication that cellular
immune responses play an important role in lesion clearance
(Nicholls and Stanley, 2000; Nicholls et al., 2001a, 2001b).
In spontaneously regressing COPV-associated papillomas, a
marked influx of CD4+ and CD8+ T cells has been observed
to correlate spatially and temporally with wart regression
(Nicholls and Stanley, 2000). While CD8+ cytotoxic T cells
could be actively involved in lysis of papillomavirus-
infected cells, a localized release of IFN-g and other
cytokines by CD4+ cells could help clear viral infections
by activating macrophages, recruiting inflammatory cells
into the lesion, and inhibiting or killing infected keratino-
cytes (Malejczyk et al., 1997). Detection of strong E1- and
E2-specific ELISpot responses in the present study could be
an indication that rAd vaccines have elicited a potent anti-
viral cellular immune response in vivo as rAd-based
vaccines are known to do in other models (Shiver et al.,
2002).
This study confirms that rAd vaccines expressing codon-
optimized E1 and E2 genes can effectively reduce or
prevent papillomavirus-induced lesions. An advantage of
rAd vaccines over DNA vaccines is that the former can
recruit both potent cellular and antibody responses (Tobery
et al., 2003), while to date DNA vaccines have been
considerably less immunogenic in humans (Garcia et al.,
K.B. Johnston et al. / Virology 336 (2005) 208–218 2152004). While pre-existing antibody responses to naturally
occurring adenovirus type 5 could limit the utility of rAd5-
based vaccines, alternate use of replication-defective rAd
vaccines based on rarer serotypes or prime-boost regimens
of DNA immunization followed by rAd might circumvent
this potential drawback (Shiver and Emini, 2004).Materials and methods
Animals
Twenty-four female beagle dogs (Study #1), age 12–15
weeks, were obtained from a colony with no previous
history of COPV infection at the University of Cambridge,
England, and housed in an airspace separate from other dogs
in the building, with a virucidal (Virkon, Antec Interna-
tional, Suffolk, UK) footbath at the common entrance and
exit. Thirty-six male and female beagles (Studies #2 and
#3), age 12–20 months, were obtained from a colony with
no previous history of COPV infection at White Eagle
Laboratories (Doylestown, PA) and housed individually in
cages that were separated by barriers to prevent cross-
infection. All animal handlers wore disposable gowns,
gloves, shoe, and hair covers that were changed between
experimental groups.
Construction of synthetic genes encoding COPV E1, E2, E4,
and E7 proteins
The wild-type coding sequences used as reference for
the design of synthetic genes for COPV E1, E2, E4, and
E7 were based on the DNA sequence in GenBank
(accession no. D55633) for the complete canine oral
papillomavirus (COPV) genome. The DNA sequences for
COPV E1, E2, E4, and E7 open reading frames (ORFs)
were translated into the deduced amino acid sequences for
the corresponding COPV E1, E2, E4, and E7 proteins. For
each protein, a synthetic gene encoding the wild-type amino
acid sequence was designed using codons that are preferred
for highly expressed genes in mammalian cells (Huang et
al., 2003). The choice of codons was based on consid-
erations presented in Lathe (1985). The potential synthetic
gene sequences were then inspected for undesired sequences
that might be generated by the codon replacements (e.g.,
‘‘ATTTA’’ sequences, inadvertent creation of intron splice
junction sites, unwanted restriction sites, etc.) Codons were
then substituted, as needed, to eliminate those unwanted
sequences and/or to add useful restriction endonuclease
cleavage sites. In all cases, a ‘‘Kozak’’ CCACC sequence
was provided immediately upstream of the ATG initiation
codon plus flanking restriction sites (e.g., BglII) for
subcloning into an appropriate cloning vector. In addition,
the COPV E1 synthetic gene contained EcoRV sites
immediately internal to both the 5V and 3V BglII cloning
sites. For the COPV E2, E4, and E7 synthetic genes, PmlIsites were located immediately internal to the 5V and 3V BglII
sites.
Once a final synthetic DNA sequence was designed for
each gene, overlapping, alternating sense and antisense
oligonucleotides (ca. 80–110 nucleotides in length) were
designed which encompassed the whole length of the
synthetic gene. The resulting oligonucleotides were chemi-
cally synthesized and assembled by PCR amplification
(Haas et al., 1996; Innis, 1990).
The codon-optimized COPV E7 gene was initially
constructed to encode the wild-type COPV E7 protein
sequence. The double mutant (C24G, E26G) version of
COPV E7 was then prepared by PCR mutagenesis by
converting TGC at codon 24 to GGA and by converting
GAG at codon 26 to GGC. The methods for the PCR
mutagenesis were as previously described (Innis, 1990). The
assembled, full-length sequences were cloned into the
mammalian expression vector V1Jns which contains the
CMV promoter plus intron A and bGH terminator sequen-
ces (Shiver et al., 1996). Presence of the desired DNA
sequences was then confirmed in these constructs.
Construction of rAd expressing HPV or COPV antigens
The shuttle vector pHCMVIBGHpA1 contains Ad5
sequences from bp 1 to bp 341 and bp 3534 to bp 5798
with an expression cassette containing human cytomegalo-
virus (HCMV) promoter plus intron A and bovine growth
hormone polyadenylation signal. The adenoviral backbone
vector pAdE1-E3- (also named as pHVad1) contains all Ad5
sequences except those nucleotides encompassing the E1
and E3 region.
As a control for vaccine studies with rAd expressing the
various COPV E proteins, a recombinant, replication-
defective adenovirus expressing HPV16 L1 protein was
constructed. One of the shuttle vectors generated during this
construction was also used as a shuttle vector for con-
struction of the COPV-related adenoviruses. The plasmid
HPV16L1/V1Jns, which contains the codon-optimized
synthetic coding sequence for HPV16L1, and construction
of rAd5-HPV16 L1 were described previously (Tobery et
al., 2003).
To evaluate expression of HPV16 L1, a selected clone
was grown into large quantities through multiple rounds of
amplification in T-Rex-293 cells. Viral DNA was extracted
and confirmed by PCR and restriction enzyme analysis.
Expression of HPV16L1 was verified by immunoblot
analysis of 293 cells infected with the recombinant
adenovirus. (Expression from the CMV-TO promoter is
de-repressed in 293 cells, which do not express the
tetracycline repressor).
For construction of rAd5-COPVE1, the coding sequence
for COPV E1 was excised from V1Jns-COPV-E1 by
digestion with EcoRV and ligated with the aforementioned
EcoRV–BamHI (flush-ended) pA1-TO shuttle vector frag-
ment, yielding the shuttle vector pA1-TO-COPV-E1. This
K.B. Johnston et al. / Virology 336 (2005) 208–218216shuttle vector was then digested with SgrAI plus BstZ17I
and co-transfected into E. coli strain BJ5183 with linearized
(ClaI-digested) adenovirus vector backbone pAdE1-E3. The
resulting transformants were screened and recombinant
adenovirus, rAd5-COPVE1, was then rescued and amplified
in T-rex-293 cells as described above. Expression of COPV
E1 was verified by immunoblot analysis of 293 cells
infected with rAd.
For construction of rAd5-COPVE2, the coding sequence
for COPV E2 was excised from V1Jns-COPV-E2 by
digestion with PmlI and ligated with the aforementioned
EcoRV–BamHI (flush-ended) pA1-TO vector fragment,
yielding the shuttle vector pA1-TO-COPV-E2. This shuttle
vector was then digested with SspI plus BstZ17I and co-
transformed into E. coli strain BJ5183 with linearized (ClaI-
digested) adenovirus vector backbone pAdE1-E3- DNA as
described above. Eight single colonies were picked from the
resulting transformation plate and inoculated into 2 ml of
Terrific Broth with ampicillin (50 Ag/ml) and then grown for
8 h at 37 -C. Cells were harvested and small-scale plasmid
DNA preparations were made (pAd-TO-COPV-E2 isolates).
The plasmid DNAs for pAd-TO-COPV-E2 clones #1, 3, 5,
and 7 were then transformed into E. coli Stbl2-competent
cells. Two colonies for each original DNA (colonies 1-1, 1-2,
3-1, 3-2, 5-1, 5-2, 7-1, and 7-2) were picked and grown
separately in LB with ampicillin (50 Ag/ml) overnight at 37
-C. Large-scale plasmid DNA preparations were then made
for pAd-TO-COPV-E2 isolates #7-1 and #7-2. Both purified
DNAs were digested with HindIII and XhoI to confirm that
they had the correct structure. Both pAd-TO-COPV-E2
isolates #7-1 and #7-2 were digested with PacI and trans-
fected into T-REx-293 cells using GTS Geneporter trans-
fection reagent. Six days later, several plaques were picked
and grown in T-REx-293 cells in 35-mm plates. Based on
PCR analysis of the adenoviral DNA, clone #7.1B of Ad-
TO-COPV-E2 was selected for further evaluation. This
isolate was grown into large quantities through multiple
rounds of amplification in T-REx-293 cells. The virus was
then purified by banding on CsCl equilibrium density
gradients. Viral DNA was purified and the structure was
confirmed by digestion with the restriction enzymes HindIII
and XhoI. Expression of COPV E2 was verified by
immunoblot analysis of 293 cells infected with recombinant
rAd5-COPVE2.
For construction of rAd5-COPVE4 and rAd5-COPVE7,
the coding sequences for COPV E4 and COPV E7 (C24G,
E26G double mutant) were excised from V1Jns-COPV-E4
and V1Jns-COPV-E7, respectively, by digestion with PmlI.
The gene fragments were ligated with the aforementioned
EcoRV–BamHI (flush-ended) pA1-TO vector fragment,
yielding the shuttle vectors pA1-TO-COPV-E4 and pA1-
TO-COPV-E7, respectively. The subsequent steps of
recombination with the pAdE1-E3- vector backbone and
the rescue and amplification of the resulting recombinant
Ad5-COPVE4 and Ad5-COPVE7 viruses in T-REx-293
cells were as described above. Expression of COPV E4 andCOPV E7 was verified by immunoblot analyses of 293 cells
infected with the corresponding rAd.
In vitro expression
Protein expression was evaluated by infection of 293
(transformed embryonic human kidney) or T rex 293 cells
using either 108 or 109 particles of adenoviral vectors
carrying respective COPV E1, E2, E4, E7, or HPV L1
genes. Infected cells were harvested at 48 h post-infection.
The pellets of infected cells were suspended in 200 Al of 2
Tris-glycine SDS buffer. The samples were frozen/thawed 3
times. The resulting cell lysates were clarified by centrifu-
gation at 4 -C for 15 min at 14,000 rpm in a micro-
centrifuge. Equivalent amounts of total lysate protein were
electrophoresed on SDS–PAGE gels followed by immuno-
blotting to nitrocellulose or PVDF membranes. The
immunoblots were analyzed using goat sera prepared to
each of the COPV proteins. For all four COPV proteins [E1,
E2, E4, and E7 (C24G, E26G)], the results verified
significant expression of a protein of the expected size
which reacted with the corresponding antisera.
Immunization with rAd-COPV E vaccines and challenge
with COPV
Beagle dogs were injected subcutaneously with 1011 rAd
particles/dose of rAd-COPV E1, rAd-COPV E2, rAd-COPV
E1 + E2, rAd-COPV E4 + E7, rAd-COPV E1 + E2 + E4 +
E7, or rAd-HPV 16 L1 (negative control) vaccines and were
boosted 4 weeks later. Combined vaccines were prepared by
mixing rAd constructs prior to immunization. Four (Study
#1) to six (Studies 2, 3) weeks after the second vaccine
injection, dogs were then challenged with COPVobtained as
previously described (Nicholls et al., 1999). Blood samples
were collected immediately prior to challenge. Weekly, oral
challenge sites were examined and photographed, the
number of warts was counted, and diameter of individual
warts was measured. At the conclusion of the study, the
animals were euthanized. Three studies were performed.
Study #1 was undertaken at the University of Cambridge,
Cambridge, UK; whereas Studies #2 and #3 were performed
at White Eagle Laboratories, Doylestown, PA, and Merck
Research Laboratories (MRL), West Point, PA, USA. J.
Monteiro (MRL) received training on administration of the
COPV challenge in the laboratory of M. Stanley, University
of Cambridge, Cambridge, UK. All experiments and
procedures were reviewed and approved by the Merck
IACUC prior to implementation.
Peripheral blood mononuclear cells (PBMC)
Blood was collected by venipuncture preceding immu-
nizations at 8–10 and 4–6 weeks before challenge with
COPV, immediately prior to challenge at week 0 and at
weeks 4, 8, 12, and 16 post-challenge. Whole blood samples
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treated and non-treated Vacutainer tubes (Sherwood) for
PBMC purification and serum. PBMCs were isolated by
density gradient centrifugation using Accuspin tubes
(Sigma). Isolated cells were diluted in R2 [RPMI 1640
with 2 mM l-glutamine, 2% heat-inactivated fetal calf
serum, 100 U penicillin/100 Ag/ml streptomycin, 10 mM
HEPES, 50 AM 2-mercaptoethanol] and centrifuged at 2000
rpm for 5 min. After resuspension in R2 and further
centrifugation, cells were resuspended in R2 and counted
using a Coulter Z1 particle counter (Beckman Coulter).
PBMCs were washed in R2, resuspended in freezing
medium (50% FCS, 40% RPMI, 10% dimethyl sulfoxide),
aliquoted, stored overnight at 70 -C, and then transferred
to a liquid nitrogen freezer until use.
COPV E1 and E2 peptides
For COPV peptides, 59 E1 and 37 E2 20-mer peptides
containing sequential 20 amino acid sequences overlapping
by 10 amino acids were synthesized by MIMOTOPES,
Victoria, Australia. E1 and E2 peptides spanned the entire
amino acid sequence of COPV E1 and E2 and were found to
have the appropriate mass for each peptide by mass
spectroscopy.
Canine IFN-c ELISpot assay
Peptide pools containing all E1 or E2 peptides (400 Ag/
ml of each peptide) in 100% tissue culture grade dimethyl
sulfoxide (DMSO, Sigma) were diluted 1/100 in RPMI
1640/10% fetal calf serum (R10) prior to use in the canine
ELISpot assay. Purified PBMCs were stimulated in vitro
with COPV E1 or E2 peptide pools or with 1% DMSO/R10
(negative control) in duplicate wells, and interferon gamma
production (IFN-g) was measured by canine IFN-g ELISpot
assay (RD Systems) according to the manufacturer’s
instructions. To assess the ability of cryopreserved cells to
produce IFN-g in response to activation, separate aliquots of
PBMC were stimulated with calcium ionomycin (0.5 Ag/ml)
and phorbol 12-myristate-13-acetate (50 ng/ml) overnight at
37 -C in a 5% CO2 humidified incubator according to the
manufacturer’s instructions and evaluated in the canine IFN-
g ELISpot assay.References
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